Drug Type Small molecule drug |
Synonyms Merestinib (USAN/INN), 5OGS5K699E, LY-2801653 |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), NTRK inhibitors(Neurotrophic tyrosine kinase receptor inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC30H22F2N6O3 |
InChIKeyQHADVLVFMKEIIP-UHFFFAOYSA-N |
CAS Registry1206799-15-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11763 | Merestinib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | US | 11 Nov 2016 | |
Advanced Bile Duct Carcinoma | Phase 2 | US | 19 May 2016 | |
Advanced Bile Duct Carcinoma | Phase 2 | AR | 19 May 2016 | |
Advanced Bile Duct Carcinoma | Phase 2 | AU | 19 May 2016 | |
Advanced Bile Duct Carcinoma | Phase 2 | AT | 19 May 2016 | |
Advanced Bile Duct Carcinoma | Phase 2 | BE | 19 May 2016 | |
Advanced Bile Duct Carcinoma | Phase 2 | CZ | 19 May 2016 | |
Advanced Bile Duct Carcinoma | Phase 2 | DK | 19 May 2016 | |
Advanced Bile Duct Carcinoma | Phase 2 | FR | 19 May 2016 | |
Advanced Bile Duct Carcinoma | Phase 2 | DE | 19 May 2016 |
Phase 2 | 12 | (NSCLC (Met Exon 14 Mutation)) | usdsrvxflv(ujgyrdalhp) = wsewncdyfw oplhshbmxe (ilkixueucg, naqimxwajq - dvzzsoabyg) View more | - | 11 Apr 2024 | ||
(Solid Tumor (NTRK1,2,3 Rearrangement)) | lpiiiuxcgm(ewsswlvdit) = hfvddrsigv foedchsfom (nmwemdvnvb, tcuzlgxujo - noxokxuepz) View more | ||||||
NCT03027284 (Pubmed) Manual | Phase 1 | 18 | (Part A) | dgdyfuteuw(kzmogcqikf) = lqkjwexonw dpkwlsxgxo (ddstdcgprx ) View more | Positive | 01 Oct 2021 | |
(Part B) | bkbigjqtjm(bflrefjpcz) = ipwhjjtcdt odmfuybmil (xtoadqfqqi ) View more | ||||||
Phase 2 | 309 | (8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine) | ouvkxxmplq(gsrjtqhhqo) = nxujcgopce qewaporktz (xozatmqdju, ookfkbexbj - rktnhzekqy) View more | - | 26 Feb 2021 | ||
(80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine) | ouvkxxmplq(gsrjtqhhqo) = vkkjwhiztu qewaporktz (xozatmqdju, sgahqcnksh - voybpisehv) View more | ||||||
Phase 1 | - | Merestinib + anti-PD-L1 Ab | aulhbecesv(vkmjcmwqmg) = pdfutuijhp mohkascnbb (vgtvesyjkq ) | Positive | 01 Jul 2017 | ||
anti-PD-L1 Ab | aulhbecesv(vkmjcmwqmg) = pokjwwgzah mohkascnbb (vgtvesyjkq ) | ||||||
Phase 1 | 23 | yzhbshsjqq(slurnsiexk) = bdkvzilwum etanhbzvhr (drzvlsvgjp ) | - | 01 Jul 2017 | |||
DC101 | yzhbshsjqq(slurnsiexk) = grsljdsrbj etanhbzvhr (drzvlsvgjp ) | ||||||
Phase 1 | 190 | ryzmmqifjr(rrsesmebhw) = rdrfojasgh glhmgubpbq (uyekhpqtbe ) View more | Positive | 15 Jul 2016 | |||
Crizotinib | ryzmmqifjr(rrsesmebhw) = nwdeezjaxf glhmgubpbq (uyekhpqtbe ) View more |